ISRCTN94244587 https://doi.org/10.1186/ISRCTN94244587

Renal protection by radical-scavenging with N-acetylcysteine in cardiac surgery patients

Submission date	Recruitment status	[X] Prospectively registered
01/08/2006	No longer recruiting	[_] Protocol
Registration date	**Overall study status**	[_] Statistical analysis plan
29/08/2006	Completed	[X] Results
Last Edited	**Condition category**	[_] Individual participant data
07/01/2021	Urological and Genital Diseases	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Uwe Mehlhorn

Contact details
University of Cologne
Joseph-Stelzmann-Str. 9
Cologne
Germany
50924
+49 (0) 221 478 6043
uwe.mehlhorn@uk-koeln.de

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
DFG ME 1257/3-2

Study information

Scientific Title
Renal protection by radical-scavenging with N-acetylcysteine in cardiac surgery patients

Study objectives
N-acetylcysteine (NAC) protects renal function in cardiac surgery patients subjected to Cardio-Pulmonary Bypass (CPB).

Ethics approval required
Old ethics approval format

Ethics approval(s)
The Institutional Ethics Committee of the Medical Faculty of the University of Cologne approved the study on 15th July 2005 (ref: #03-122).

Study design
Randomised, double-blind, placebo-controlled clinical trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Hospital

Study type(s)
Treatment

Participant information sheet

Health condition(s) or problem(s) studied
Renal dysfunction induced by cardiopulmonary bypass (CPB) during cardiac surgery

Interventions
NAC at 100 mg per kg of body weight into the CPB prime followed by NAC infusion at 20 mg per kg of bodyweight per hour until the end of CPB versus placebo (25 patients for each group).

In addition to the standard blood analyses urine samples will be collected. There will be no other interventions, surgical and postoperative treatment will not differ from routine (non-study) patients.

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
N-acetylcysteine

Primary outcome measure
Postoperative renal function assessed by means of the following variables in plasma and urine:
1. Creatinine concentration (primary variable)
2. Cystatin C concentration (co-primary variable)

Secondary outcome measures
1. Urea, retinol-binding protein, albumine, alpha1-microglobulin
2. Quantity of post-surgery diuretic medication, serum creatinine clearance
3. Oxidative stress variable in plasma and urine: 8-isoprostaglandinF2a

Overall study start date
01/01/2007

Completion date
31/12/2008

Eligibility

Key inclusion criteria
1. Male or female
2. No renal dysfunction requiring hemodialysis/hemofitration
3. Isolated coronary artery disease
4. Left ventricular ejection fraction more than 40%

Participant type(s)
Patient

Age group
Adult

Sex
Both

Target number of participants
50

Total final enrolment
40

Key exclusion criteria
1. Pregnancy
2. Aged over 18 years

Date of first enrolment
01/01/2007

Date of final enrolment

31/12/2008

Locations

Countries of recruitment
Germany

Study participating centre
University of Cologne
Cologne
Germany
50924

Sponsor information

Organisation
German Research Foundation (DFG) (Germany)

Sponsor details
Kennedyallee 40
Bonn
Germany
53170
+49 (0) 228 885 2239
gabriele.auster@dfg.de

Sponsor type
Research organisation

Website
http://www.dfg.de

ROR
https://ror.org/018mejw64

Funder(s)

Funder type
Research organisation

Funder Name
German Research Foundation (DFG)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/08/2005	07/01/2021	Yes	No